drugset

Drugs / CHIKUNGUNYA VIRUS, LIVE ATTENUATED

Follow last change 2 days ago re-read 3 minutes ago

CHIKUNGUNYA VIRUS, LIVE ATTENUATED

also known as Chikungunya virus lr2006 opy1 (attenuated strain) antigen · IXCHIQ

Developed for: chikungunya
Investigated by: ANRS, Emerging Infectious Diseases · ARS La Réunion · Centre Hospitalier Universitaire de la Réunion · Direction Générale de l'Offre de Soins · Région La Réunion

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Ixchiq	—	2024-06-28	europa.eu ↗

Trials 1

today

EU approved 2024

NCT06928753 · Ph 4

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT06928753	Apr 2025 → Apr 2026 overdue	chikungunya	Centre Hospitalier Universitaire de la Réunion	Recruiting	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	CHIKUNGUNYA VIRUS, LIVE ATTENUATED	ChEMBL registry synonym — accepted as the source's own label CHEMBL6068495 ↗
Known as	Chikungunya virus lr2006 opy1 (attenuated strain) antigen	ChEMBL registry synonym — accepted as the source's own label CHEMBL6068495 ↗
Known as	IXCHIQ	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06928753 ↗
Modality	Vaccine	“IXCHIQ vaccine” NCT06928753 ↗